Long Term Inhibition of Interleukin (IL)-17A with Secukinumab Improves Clinical Symptoms and Reduces Spinal Inflammation As Assessed by Magnetic Resonance Imaging in Patients with Ankylosing Spondylitis.

Míreanna comhchosúla

• Long term IL-17A inhibition by secukinumab leads to reduced spinal inflammation and unchanged fatty lesions in patients with ankylosing spondylitis
  de réir: Baraliakos, X, et al.
  Foilsithe / Cruthaithe: (2013)
• EVALUATION OF EFFICACY AND SAFETY OF SECUKINUMAB IN THE TREATMENT OF PATIENTS WITH MODERATE-TO-SEVERE ANKYLOSING SPONDYLITIS
  de réir: Emery, P, et al.
  Foilsithe / Cruthaithe: (2012)
• EARLY EFFECT OF SECUKINUMAB IN REDUCING SPINAL INFLAMMATION AS DETECTED BY MAGNETIC RESONANCE IMAGING IN PATIENTS WITH ANKYLOSING SPONDYLITIS
  de réir: Van Laar, J, et al.
  Foilsithe / Cruthaithe: (2012)
• LONG TERM INHIBITION OF IL-17A WITH SECUKINUMAB REDUCES SPINAL INFLAMMATION BUT HAS NO INFLUENCE ON FATTY LESIONS AS ASSESSED BY MAGNETIC RESONANCE IMAGING IN PATIENTS WITH ANKYLOSING SPONDYLITIS
  de réir: Baraliakos, X, et al.
  Foilsithe / Cruthaithe: (2013)
• Interleukin-17A Blockade with Secukinumab Reduces Spinal Inflammation in Patients with Ankylosing Spondylitis As Early As Week 6, As Detected by Magnetic Resonance Imaging
  de réir: Baraliakos, X, et al.
  Foilsithe / Cruthaithe: (2011)